 phase II trial carboplatin untreated patients extensive stage small cell lung cancer Twenty-five untreated patients extensive stage small cell lung cancer ESSCLC carboplatin CBDCA infusion days Thirteen patients overall response rate confidence limits complete responses CR confidence limits median duration response months median survival time months long-term survivors months start CBDCA treatment Ninety-two courses CBDCA treatment-related death main toxicity myelosuppression hematologic toxicity hemoglobin level g/dl granulocyte count count neutropenia courses patients hemoglobin level courses patients platelet count courses patients study dose schedule CBDCA active drug ESSCLC tolerable toxicity